<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863274</url>
  </required_header>
  <id_info>
    <org_study_id>Primary Prevention Program</org_study_id>
    <nct_id>NCT04863274</nct_id>
  </id_info>
  <brief_title>Influence of Additional Physician's Consultations and Short Message Service (SMS) Reminders to Patient Compliance</brief_title>
  <acronym>3P</acronym>
  <official_title>The Program to Assess the Influence of Routing and In-depth Consultation of Patients With Cardiovascular Risk Factors on the Choice of Medicine and Treatment Compliance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The League of Clinical Research, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Research Center for Preventive Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The League of Clinical Research, Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A systematic collection of retrospective and prospective data based on non-interventional&#xD;
      patient observation, aimed to assess the risks, course and outcomes of a disease or a group&#xD;
      of diseases:&#xD;
&#xD;
        -  the retrospective part: database of patients with cardiovascular risks;&#xD;
&#xD;
        -  the prospective part: observation of patients in the real world medical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research program will have two parts:&#xD;
&#xD;
      Stage 1: identification of patients with moderate, high and very high cardiovascular risk,&#xD;
      not having diseases of atherosclerotic genesis and requiring lipid-lowering drugs.&#xD;
&#xD;
      Stage 2: a prospective observation of patients receiving primary medical prophylaxis of CVD&#xD;
      with atorvastatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2018</start_date>
  <completion_date type="Actual">October 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Target level of LDL cholesterol</measure>
    <time_frame>12 months</time_frame>
    <description>To assess number of patients achieving the target level of low-density lipoprotein cholesterol in study group and in control group.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2912</enrollment>
  <condition>Lipid Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>Expanded consultation group</arm_group_label>
    <description>In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins.&#xD;
Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre.</description>
    <arm_group_label>Expanded consultation group</arm_group_label>
    <other_name>SMS and phone call reminders</other_name>
    <other_name>Patients' consultations</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The total population of patients (2912 people) will be divided into three strata:&#xD;
&#xD;
        patients with moderate risk of CVD (1242 patients) patients with high risk of CVD (1044&#xD;
        patients) patients with very high risk of CVD (626 patients). The subjects are randomized&#xD;
        to a study or control group in each stratum in the ratio of 1: 1&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Data on the following subjects is planned to be collected in the project:&#xD;
&#xD;
          -  Aged from 40 to 65 years inclusively&#xD;
&#xD;
          -  With a high (≥5%) cardiovascular risk measured by SCORE and low density lipoprotein&#xD;
             (LDL) levels of ≥2,5 mmol/L, or with a very high (≥10%) cardiovascular risk measured&#xD;
             by SCORE and LDL levels ≥1,8 mmol/L or With atherosclerotic stenosis of&#xD;
             brachiocephalic arteries of &gt;50% in the absence of cerebrovascular disease&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  No contraindications to statin treatment and not taking stating at study entry.&#xD;
&#xD;
          -  History of the following clinically significant events and conditions:&#xD;
&#xD;
             (а) myocardial infarction (б) stroke (в) transient ischemic attack&#xD;
&#xD;
          -  Presence of the following diseases at the time of a statin administration:&#xD;
&#xD;
             (а) ischemic heart disease (б) heart failure (в) peripheral artery atherosclerosis (г)&#xD;
             atherosclerotic stenosis of brachiocephalic arteries with cerebrovascular disease .&#xD;
&#xD;
        Subjects must give their consent for processing of their personal data for the purposes of&#xD;
        this scientific project.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svetlana I Elkonina, MD</last_name>
    <role>Study Director</role>
    <affiliation>League of Clinical Research (LeagueCRR)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>League of Clinical Research (LeagueCRR)</name>
      <address>
        <city>Moscow</city>
        <zip>119590</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention of cardiovascular diseases</keyword>
  <keyword>atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04863274/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

